De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

cbdMD Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

T. Kennedy

Algemeen directeur

US$275.0k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	4yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	5.5yrs

Recente managementupdates

Recent updates

cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

Mar 23

This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

Feb 23

If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

Feb 09

We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

Jan 13

Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

Dec 15

Analyse CEO-vergoeding

Hoe is T. Kennedy's beloning veranderd ten opzichte van cbdMD's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$23m
Mar 31 2024	n/a	n/a	-US$26m
Dec 31 2023	n/a	n/a	-US$24m
Sep 30 2023	US$275k	US$275k	-US$27m
Jun 30 2023	n/a	n/a	-US$26m
Mar 31 2023	n/a	n/a	-US$56m
Dec 31 2022	n/a	n/a	-US$59m
Sep 30 2022	US$558k	US$276k	-US$74m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$29m
Dec 31 2021	n/a	n/a	-US$37m
Sep 30 2021	US$720k	US$247k	-US$26m

Compensatie versus markt: De totale vergoeding ($USD 275.00K ) T. } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).

Compensatie versus inkomsten: De vergoeding van T. is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

T. Kennedy (44 yo)

4yrs

Tenure

US$275,000

Compensatie

Mr. T. Ronan Kennedy has been the Chief Financial Officer at cbdMD, Inc., since October 1, 2020 and serves as its Interim Chief Executive Officer and Principal Executive Officer since March 1, 2023 and ser...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
T. Kennedy	Interim CEO	4yrs	US$275.00k	0.11% $ 1.9k
Sibyl Swift	CSO, VP of Regulatory Affairs & Director	3.6yrs	US$6.70k	0.10% $ 1.8k
Bradley Whitford	Chief Accounting Officer	less than a year	geen gegevens	0.012% $ 200.1
Zeb Booker	Chief Technology Officer	5.8yrs	geen gegevens	geen gegevens
John Weston	Director of Investor Relations	no data	geen gegevens	geen gegevens
Lance Blundell	General Counsel	5.8yrs	geen gegevens	geen gegevens
Robert Pettway	Director of Public Relations	no data	geen gegevens	geen gegevens
Francisco Mangual	Senior VP of Sales	5.9yrs	geen gegevens	geen gegevens
Shannon Charles	Chief Marketing Officer	1.8yrs	geen gegevens	geen gegevens
David Johnson	Senior VP of Business Development	2.8yrs	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

44.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van YCBD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sibyl Swift	CSO, VP of Regulatory Affairs & Director	2.2yrs	US$6.70k	0.10% $ 1.8k
Scott Stephen	Independent Chairman	5.5yrs	US$53.95k	0.16% $ 2.8k
William Raines	Independent Director	5.5yrs	US$62.70k	2.17% $ 37.5k
Bakari Sellers	Independent Director	7.6yrs	US$60.82k	0.14% $ 2.4k

5.5yrs

Gemiddelde duur

50.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van YCBD wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.5 jaar).

cbdMD Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

cbdMD, Inc., Annual General Meeting, Mar 29, 2024

cbdMD Appoints Shannon Charles as Chief Marketing Officer

cbdMD, Inc., Annual General Meeting, Feb 16, 2023

Insufficient new directors

cbdMD, Inc. Announces Resignation of Martin Sumichrast as CEO

cbdMD, Inc. Announces Board Changes

Recent updates

cbdMD, Inc. Announces Acceptance of Compliance Plan by NYSE American

Consensus EPS estimates upgraded to US$2.63 loss

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

cbdMD Receives Non-Compliance Letter from NYSE American Regarding Shareholders Equity

Consensus revenue estimates fall by 12%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

cbdMD, Inc., Annual General Meeting, Mar 29, 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Full year 2023 earnings: EPS and revenues miss analyst expectations

No longer forecast to breakeven

New major risk - Share price stability

Third quarter 2023 earnings released: US$1.16 loss per share (vs US$24.76 loss in 3Q 2022)

Second quarter 2023 earnings released: US$1.74 loss per share (vs US$4.32 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.082 loss per share (vs US$0.35 loss in 1Q 2022)

cbdMD Appoints Shannon Charles as Chief Marketing Officer

cbdMD, Inc., Annual General Meeting, Feb 16, 2023

Full year 2022 earnings released: US$1.24 loss per share (vs US$0.47 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

cbdMD, Inc. Announces Resignation of Martin Sumichrast as CEO

cbdMD, Inc. Announces Board Changes

Insufficient new directors

cbdMD, Inc. Announces Resignation of Scott Coffman as Co-Chief Executive Officer

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

cbdMD Requests the Food and Drug Administration (FDA) Remove the Drug Exclusion for CBD and Review cbdMD’s Extensive Safety Submission

cbdMD Becomes First American CBD Brand to Receive Validation by the United Kingdom Food Standards Agency

cbdMD, Inc. Becomes the First CBD Company to Earn NSF International’s Certified for Sport Certification

cbdMD, Inc., Annual General Meeting, Mar 11, 2022

cbdMD, Inc. Withdraws Revenue Guidance for the Quarter Ending December 31, 2021

cbdMD, Inc. Launches New Full Spectrum Product Line

cbdMD, Inc. Revises Sales Guidance for the First Quarter of Fiscal 2022

Third quarter 2021 earnings released: EPS US$0.017 (vs US$0.18 loss in 3Q 2020)

Consensus EPS estimates fall to -US$0.45

Second quarter 2021 earnings released: US$0.24 loss per share (vs US$0.41 profit in 2Q 2020)

cbdMD, Inc. Provides Net Sales Guidance for the First Quarter of Fiscal 2022

cbdMD (NYSEMKT:YCBD) Has Debt But No Earnings; Should You Worry?

cbdMD, Inc. Elects Sim Farar as Director

Chairman & Co-CEO recently sold US$240k worth of stock

cbdMD, Inc. Announces Order by Court Staying California Litigation

Independent Director recently sold US$81k worth of stock

cbdMD, Inc. Appoints T. Ronan Kennedy to Serve as Chief Operating Officer

Independent Director notifies of intention to sell stock

Chairman & Co-CEO recently sold US$1.8m worth of stock

This Insider Has Just Sold Shares In cbdMD, Inc. (NYSEMKT:YCBD)

Chairman & Co-CEO notifies of intention to sell stock

Price target raised to US$6.03

First quarter 2021 earnings released: US$0.18 loss per share (vs US$0.47 profit in 1Q 2020)

Revenue and earnings beat expectations

Analysts update estimates

If You Had Bought cbdMD (NYSEMKT:YCBD) Stock A Year Ago, You Could Pocket A 383% Gain Today

Investor sentiment improved over the past week

New 90-day high: US$4.14

Price target raised to US$5.77

cbdMD, Inc., Annual General Meeting, Mar 12, 2021

We Wouldn't Rely On cbdMD's (NYSEMKT:YCBD) Statutory Earnings As A Guide

New 90-day high: US$3.40

Investor sentiment improved over the past week

cbdMD Enters Global Beauty and Skincare Market With Launch of “cbdMD Botanicals”

Price target raised to US$5.53

Revenue beats expectations, earnings disappoint

Full year 2020 earnings released: EPS US$0.28

New 90-day high: US$3.36

Is cbdMD (NYSEMKT:YCBD) Using Debt Sensibly?

New 90-day high: US$3.01

Market bids up stock over the past week

New 90-day low: US$1.84

Pro Group, Inc. Selects cbdMD and Paw CBD as Exclusive Distributor of CBD Brands

cbdMD, Inc Announces Resignation of Mark Elliott as Chief Operating Officer, effective October 01, 2020